Gut Bacterial Tyrosine Decarboxylase Associates with Clinical Variables in a Longitudinal Cohort Study of Parkinsons Disease
Open accessPublished version of a preprint
Abstract
Gut microbiota influences the clinical response of a wide variety of orally administered drugs. However, the underlying mechanisms through which drug-microbiota interactions occur are still obscure. Previously, we reported that tyrosine decarboxylating (TDC) bacteria may restrict the levels of levodopa reaching circulation in patients with Parkinson's disease (PD). We observed a significant positive association between disease duration and the abundance of the bacterial tdc-gene. The question arises whether increased exposure to anti-PD medication could affect the abundance of bacterial TDC, to ultimately impact drug efficacy. To this end, we investigated the potential association between anti-PD drug exposure and bacterial tdc-gene abundance over a period of 2 years in a longitudinal cohort of PD patients and healthy controls. Our data reveal significant associations between tdc-gene abundance, several anti-PD medications, including entacapone, rasagiline, pramipexole, and ropinirole but not levodopa, and gastrointestinal symptoms, warranting further research on the effect of anti-PD medication on microbial changes and gastrointestinal function.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Lack of sufficient comparisons between microbial profiles from patients under conventional pharmacological treatment versus treatment-naïve PD individuals limits diagnostic applicability, since drugs intake may greatly affect GM composition.
“Moreover, the lack of sufficient comparisons between microbial profiles obtained from patients under conventional pharmacological treatment versus treatment-naïve PD individuals limits their diagnostic applicability, since drugs intake may greatly affect GM composition [185,186,188].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [188]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · see citing works
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856 · see citing works
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R. L., Patel, S., Rick, C., Gray, R. G., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219 · see citing works
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837 · see citing works
Population-level analysis of gut microbiome variation
Falony, G., Joossens, M., Vieira-Silva, S., Wang, J., Darzi, Y., Faust, K., Kurilshikov, A., Bonder, M. J., Valles-Colomer, M., Vandeputte, D., et al. (2016) · Science · doi:10.1126/science.aad3503 · Cited by 2,400 · see citing works
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968 · see citing works
Self-citationAssessment of Soil Microbial Community Structure by Use of Taxon-Specific Quantitative PCR Assays
Fierer, N., Jackson, J. A., Vilgalys, R. J., & Jackson, R. B. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.7.4117-4120.2005 · Cited by 1,571 · see citing works
A constipation scoring system to simplify evaluation and management of constipated patients
Agachan, F., Chen, T., Pfeifer, J., Reissman, P., & Wexner, S. D. (1996) · Diseases of the Colon & Rectum · doi:10.1007/bf02056950 · Cited by 1,256 · see citing works
Gastrointestinal Dysfunction in Parkinson’s Disease
Fasano, A., Visanji, N. P., Liu, L. W. C., Lang, A. E., & Pfeiffer, R. F. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00007-1 · Cited by 1,016 · see citing works
Gastrointestinal dysfunction in Parkinson's disease
Pfeiffer, R. F. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00307-7 · Cited by 925 · see citing works
Hill‐Burns, E. M., Debelius, J. W., Morton, J. T., Wissemann, W. T., Lewis, M. R., Wallen, Z. D., Peddada, S. D., Factor, S. A., Molho, E., Zabetian, C. P., et al. (2017) · Movement Disorders · doi:10.1002/mds.26942 · Cited by 874 · see citing works
Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., & Balskus, E. P. (2019) · Science · doi:10.1126/science.aau6323 · Cited by 753 · see citing works
van Kessel, S. P., Frye, A. K., El-Gendy, A. O., Castejon, M., Keshavarzian, A., van Dijk, G., & El Aidy, S. (2019) · Nature Communications · doi:10.1038/s41467-019-08294-y · Cited by 521 · see citing works
Singaram, C., Gaumnitz, E., Torbey, C., Ashraf, W., Quigley, E. M., Sengupta, A., & Pfeiffer, R. F. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92707-7 · Cited by 364 · see citing works
Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression
Aho, V. T. E., Pereira, P. A. B., Voutilainen, S., Paulin, L., Pekkonen, E., Auvinen, P., & Scheperjans, F. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.05.064 · Cited by 361 · see citing works
Self-citationANDERSON, G., Noorian, A. R., Taylor, G. T., Anitha, M., BERNHARD, D., SRINIVASAN, S., & GREENE, J. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.05.010 · Cited by 238 · see citing works
Boertien, J. M., Pereira, P. A. B., Aho, V. T. E., & Scheperjans, F. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191711 · Cited by 169 · see citing works
Self-citationWeis, S., Schwiertz, A., Unger, M. M., Becker, A., Faßbender, K., Ratering, S., Kohl, M., Schnell, S., Schäfer, K.-H., & Egert, M. (2019) · npj Parkinson s Disease · doi:10.1038/s41531-019-0100-x · Cited by 145 · see citing works
Kulisevsky, J., & Pagonabarraga, J. (2010) · Drug Safety · doi:10.2165/11319860-000000000-00000 · Cited by 83 · see citing works
Torriani, S., Gatto, V., Sembeni, S., Tofalo, R., Suzzi, G., Belletti, N., Gardini, F., & Bover‐Cid, S. (2008) · Journal of Food Protection · doi:10.4315/0362-028x-71.1.93 · Cited by 77 · see citing works
Gut bacterial deamination of residual levodopa medication for Parkinson’s disease
van Kessel, S. P., de Jong, H. R., Winkel, S. L., van Leeuwen, S. S., Nelemans, S. A., Permentier, H. P., Keshavarzian, A., & Aidy, S. E. (2020) · BMC Biology · doi:10.1186/s12915-020-00876-3 · Cited by 57 · see citing works
van Kessel, S. P., & Aidy, S. E. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01087 · Cited by 53 · see citing works
Bacterial Metabolites Mirror Altered Gut Microbiota Composition in Patients with Parkinson’s Disease
van Kessel, S. P., & Aidy, S. E. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191780 · Cited by 52 · see citing works
Kenna, J. E., Bakeberg, M. C., Gorecki, A. M., Tay, C. Y., Winter, S., Mastaglia, F. L., & Anderton, R. S. (2020) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13134 · Cited by 27 · see citing works
Khoshbin, K., Hassan, A., & Camilleri, M. (2020) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000001003 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management
Warnecke, T., Schäfer, K., Claus, I., Tredici, K. D., & Jost, W. H. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00295-x · Cited by 189 · see citing works
Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease
Leta, V., Klingelhoefer, L., Longardner, K., Campagnolo, M., Çotur, H., Aureli, F., Metta, V., Bhidayasiri, R., Chung‐Faye, G., Falup‐Pecurariu, C., et al. (2023) · European Journal of Neurology · doi:10.1111/ene.15734 · Cited by 127 · see citing works
Mechanisms of peripheral levodopa resistance in Parkinson’s disease
Beckers, M., Bloem, B. R., & Verbeek, M. M. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00321-y · Cited by 126 · see citing works
Varesi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88 · see citing works
Zhang, Y., He, X., Qian, Y., Xu, S., Mo, C., Yan, Z., Yang, X., & Xiao, Q. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00312-z · Cited by 78 · see citing works
Lubomski, M., Xu, X., Holmes, A. J., Muller, S., Yang, J. Y. H., Davis, R. L., & Sue, C. M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.875261 · Cited by 59 · see citing works
Menozzi, E., & Schapira, A. H. V. (2024) · CNS Drugs · doi:10.1007/s40263-024-01073-4 · Cited by 47 · see citing works
A structural metagenomics pipeline for examining the gut microbiome
Walker, M. E., Simpson, J. B., & Redinbo, M. R. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102416 · Cited by 35 · see citing works
Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease
Boertien, J. M., Murtomäki, K., Pereira, P. A. B., van der Zee, S., Mertsalmi, T. H., Levo, R., Nojonen, T., Mäkinen, E., Jaakkola, E., Laine, P., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00395-8 · Cited by 34 · see citing works
Self-citationRelationship among Parkinson’s disease, constipation, microbes, and microbiological therapy
Yuan, X.-Y., Chen, Y., & Liu, Z. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i3.225 · Cited by 35 · see citing works
Microbial metabolism marvels: a comprehensive review of microbial drug transformation capabilities
Martinelli, F., & Thiele, I. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2387400 · Cited by 33 · see citing works
Does gut brain axis has an impact on Parkinson’s disease (PD)?
Elangovan, A., Dahiya, B., Kirola, L., Iyer, M., Jeeth, P., Maharaj, S., Kumari, N., Lakhanpal, V., Michel, T. M., Rao, K. R. S. S., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102171 · Cited by 22 · see citing works
Hu, X., Yu, L., Li, Y., Li, X., Zhao, Y., Xiong, L., Ai, J., Chen, Q., Wang, X., Chen, X., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14383 · Cited by 19 · see citing works
The Role of an Altered Gut Microbiome in Parkinson’s Disease: A Narrative Review
Hashish, S. A., & Salama, M. (2023) · Applied Microbiology · doi:10.3390/applmicrobiol3020030 · Cited by 17 · see citing works
Miyaue, N., Yamamoto, H., Liu, S., Ito, Y., Yamanishi, Y., Ando, R., Suzuki, Y., Mogi, M., & Nagai, M. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00903-6 · Cited by 16 · see citing works
Barbu, A. C., Stoleru, S., Zugravu, A., Poenaru, E., Dragomir, A.-F., Costescu, M., Aurelian, S. M., Shhab, Y., Stoleru, C. M., Coman, O. A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010271 · Cited by 15 · see citing works
Hong, J. P., Shin, S., Chung, S. H., Song, M.-C., Shim, J., Kim, Y., Lee, B., Yeom, M., Park, H., Jung, K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-77038-w · Cited by 15 · see citing works
Metagenome-assembled microbial genomes from Parkinson’s disease fecal samples
Duru, I. C., Lecomte, A., Shishido, T. K., Laine, P., Suppula, J., Paulin, L. G., Scheperjans, F., Pereira, P. A. B., & Auvinen, P. (2024) · Scientific Reports · doi:10.1038/s41598-024-69742-4 · Cited by 11 · see citing works
Self-citationComputational analysis of the gut microbiota-mediated drug metabolism
Chum, S., Montalvo, A. N., & Hassoun, S. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.03.016 · Cited by 8 · see citing works
A drug–microbiome–drug interaction impacts co-prescribed medications for Parkinson’s disease
Verdegaal, A. A., Oh, J., Javdan, B., Wang, R., Wu, Q., Wang, T. R. W., González-Hernández, J. A., Donia, M. S., Crawford, J. M., & Goodman, A. L. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02299-2 · Cited by 6 · see citing works
Diversity of Neurotransmitter-Producing Human Skin Commensals
Rahmdel, S., Purkayastha, M., Nega, M., Liberini, E., Li, N., Luqman, A., Brüggemann, H., & Götz, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212345 · Cited by 5 · see citing works
Forging the microbiome to help us live long and prosper
Rock, R. R., & Turnbaugh, P. J. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002087 · Cited by 5 · see citing works
Duru, I. C., Lecomte, A., Laine, P., Shishido, T. K., Suppula, J., Paulin, L. G., Scheperjans, F., Pereira, P. A. B., & Auvinen, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-96924-5 · Cited by 5 · see citing works
Self-citationKim, D., Nguyen, T. T. M., Moon, Y., Kim, J., Nam, H., Seok, D., An, Y. J., de Guzman, A. C. V., & Park, S. (2024) · Small Methods · doi:10.1002/smtd.202400469 · Cited by 4 · see citing works
Fecal tyrosine decarboxylase and motor response complications in Parkinson's disease
Hor, J. W., Lim, S., Toh, T. S., Chong, C. W., Teh, C. S. J., Song, S., & Tan, A. H. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107947 · Cited by 2 · see citing works
Feng, Y., Zhang, R., Wen, G., Xie, L., Chen, T., & Liu, W. (2025) · BMC Neurology · doi:10.1186/s12883-025-04428-6 · Cited by 2 · see citing works
Manfready, R. A., Goetz, C. G., & Keshavarzian, A. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.07.008 · Cited by 2 · see citing works
Dopaminergic Medication Accentuates Fecal Gut Microbiome Changes in Parkinson’s DiseasePreprint
Boertien, J. M., Pereira, P. A., Laine, P., Paulin, L. G., van der Zee, S., Auvinen, P., Scheperjans, F., & van Laar, T. (2022) · medRxiv · doi:10.1101/2022.12.23.22283907 · Cited by 2 · see citing works
Self-citationKim, D., Li, M., Nguyen, T. H., Choi, Y., Jang, S., Kim, M., Kim, Y. W., Shin, M., de Guzman, A. C. V., & Park, S. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2695485 · Cited by 1 · see citing works
Impact of Intestinal Bacteria on Levodopa Pharmacokinetics in Patients with Parkinson's Disease
Miyaue, N. (2024) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.55.5_223
The gut microbiome in neurodegeneration: A metagenomics and bioinformatics perspective
Muthukumar, G., Goyal, S., & Saraboji, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29932-2.00006-2
Inhibitors of gut bacterial L-dopa decarboxylation with reduced susceptibility to host metabolismPreprint
Narayan, R., Le, C. "., Khurana, J. K., Nieto, V., Olson, C. A., Turnbaugh, P. J., & Balskus, E. P. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.08.717077
Madny, M. A., & Yadav, K. S. (2026) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2026.115179
Vishwas, G., Kakkar, A. K., Mehta, S., Pattanaik, S., Bhattacharyya, S., Sharma, V., & Modi, M. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09307-7
- Authors
- van Kessel, S. P., Auvinen, P., Scheperjans, F., & El Aidy, S.
- Affiliations
- University of Helsinki (FI)
- Corresponding author
- Scheperjans, Filip
- Venue
- npj Parkinson s Disease
- Published
- 2021-12-15
- Volume
- 7
- Issue
- 1
- Pages
- 115-115
- ISSN
- 2373-8057 (ISSN-L)
- PMC
- PMC8674283
- OpenAlex
- W4200357153
- Cited by
- 34
- References
- 25
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 8 · 2023: 5 · 2022: 9
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- npj Parkinson s Disease (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Työväentutkimus Vuosikirja (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- Weston Brain Institute
- Michael J. Fox Foundation for Parkinson’s Research
- Academy of Finland (295724, 310835)
- Helsingin ja Uudenmaan Sairaanhoitopiiri (T1010NL101, TYH2018224, TYH2020335)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- Parkinson's disease, gut microbiota, tyrosine decarboxylase, levodopa, drug-microbiota interactions, entacapone, rasagiline, pramipexole, ropinirole, gastrointestinal symptoms, disease duration, longitudinal cohort
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
